DexCom Inc. (DXCM) Position Held by FTB Advisors Inc.
FTB Advisors Inc. continued to hold its position in DexCom Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,780 shares of the medical device company’s stock at the end of the second quarter. FTB Advisors Inc.’s holdings in DexCom were worth $299,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in DXCM. Aperio Group LLC boosted its position in DexCom by 100.8% in the first quarter. Aperio Group LLC now owns 6,633 shares of the medical device company’s stock valued at $450,000 after buying an additional 3,330 shares during the last quarter. Teachers Advisors Inc. boosted its stake in DexCom by 6.9% in the first quarter. Teachers Advisors Inc. now owns 174,684 shares of the medical device company’s stock worth $11,863,000 after buying an additional 11,291 shares in the last quarter. Prudential Financial Inc. boosted its stake in DexCom by 37.9% in the first quarter. Prudential Financial Inc. now owns 138,269 shares of the medical device company’s stock worth $9,390,000 after buying an additional 38,032 shares in the last quarter. BlackRock Inc. boosted its stake in DexCom by 314.5% in the first quarter. BlackRock Inc. now owns 9,321 shares of the medical device company’s stock worth $633,000 after buying an additional 7,072 shares in the last quarter. Finally, BlackRock Group LTD boosted its stake in DexCom by 17.6% in the first quarter. BlackRock Group LTD now owns 69,904 shares of the medical device company’s stock worth $4,747,000 after buying an additional 10,465 shares in the last quarter. Institutional investors own 99.37% of the company’s stock.
Shares of DexCom Inc. (NASDAQ:DXCM) traded down 0.45% during mid-day trading on Friday, hitting $81.61. The stock had a trading volume of 592,506 shares. DexCom Inc. has a 52 week low of $47.92 and a 52 week high of $96.38. The stock’s market cap is $6.85 billion. The stock has a 50-day moving average price of $89.90 and a 200 day moving average price of $78.39.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The company had revenue of $137.30 million for the quarter, compared to analysts’ expectations of $132.48 million. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. The company’s revenue was up 47.3% on a year-over-year basis. On average, equities analysts forecast that DexCom Inc. will post ($0.57) EPS for the current fiscal year.
A number of brokerages have commented on DXCM. JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a report on Monday, June 20th. Zacks Investment Research cut DexCom from a “hold” rating to a “sell” rating in a report on Tuesday, June 28th. Canaccord Genuity reiterated a “buy” rating and set a $95.00 target price on shares of DexCom in a report on Wednesday, July 13th. Jefferies Group reiterated a “buy” rating and set a $98.00 target price (up previously from $90.00) on shares of DexCom in a report on Friday, July 15th. Finally, Deutsche Bank AG increased their price target on DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $95.08.
In other news, SVP Jeffrey Moy sold 12,843 shares of the business’s stock in a transaction on Tuesday, July 19th. The shares were sold at an average price of $83.78, for a total transaction of $1,075,986.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Lister sold 3,560 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $84.41, for a total transaction of $300,499.60. The disclosure for this sale can be found here. Insiders own 2.80% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.